Table 1.
Clinicopathological features of 298 colorectal cancer patients.
Table 2.
Oligonucleotide sequences of 19 target genes.
Fig 1.
(A) Schematic representation of the colorectal cancer biomarker chip evacuated using the weighted enzymatic chip array method with the 19 candidate genes, a positive control (β-actin), a negative control (Oryza sativa), and a blank control (double distilled water). Oligonucleotide fragments were blotted on the membranes in triplicate, and the expression levels of each gene spot were quantified and then normalized on the basis of the color density of a reference gene (β-actin). (B) Positive biochip result. (C) Negative biochip result.
Table 3.
Comparison between non-relapsed and relapsed colorectal cancer patients.
Table 4.
Factors influencing the relapse estimated by univariate and multivariate logistic regression analyses.
Table 5.
Sensitivity, specificity, postitive predictive value, negative predictive value, and accuracy of postoperative serum CEA level and biomarker chip.
Table 6.
Clinical features associated with diagnostic/prognostic values of postoperative CEA and the biochip.
Table 7.
Comparison of the expression prior to the diagnosis in 48 relapsed patients.
Fig 2.
(A) Cumulative disease-free survival (DFS) and (B) overall survival (OS) rates of the 298 colorectal cancer patients calculated using the Kaplan—Meier method.
Positive biochip results correlated strongly with lower DFS and OS rates of colorectal cancer patients (both P < 0.001).